Du är här

2016-02-15

Enzymatica AB: Bulletin from the extraordinary shareholders' meeting in Enzymatica

Today
on 15 February 2016, an extra general meeting was held in Enzymatica AB (publ)
("Enzymatica"). A summary of the resolutions adopted follows below. All
resolutions were adopted unanimously.

Acquisition of Zymetech by way of issue in kind of shares and warrants

The meeting resolved in accordance with the proposal of the board of directors
to approve the acquisition of 2,142,658 shares in Zymetech ehf. ("Zymetech")
through a way of issue in kind of maximum 20,905,942 shares and 3,982,084
warrants in Enzymatica, which only can be subscribed by the shareholders in
Zymetech. Subscription and contribution in kind shall be made on 31 May 2016
at the latest.

The assets to be contributed in kind are estimated to be entered in
Enzymaticas balance sheet at a value of SEK 73,243,380, out of which SEK
70,034,906 pertains to the new shares and SEK 3,208,474 pertains to the
warrants. Subsequently, the new shares are estimated to be issued at an
average subscription price of approximately SEK 3.35 and the warrants at an
average value of approximately SEK 0.81. The final value whereby the
contribution in kind will be included in the balance sheet of Enzymatica and
subsequently the final subscription price of the shares and the warrants,
will, in accordance with the applicable accounting rules, be determined based
on the market price of the shares of Enzymatica at the time of the closing of
the transaction.

Enzymaticas share capital may increase with SEK 836,241.30 through the new
issue of shares. Upon exercise of the warrants, the share capital of
Enzymatica may increase with an amount up to SEK 159,284.05.

Election of new members of the board of directors

The meeting resolved in accordance with the proposal of the board of directors
that the board of directors, until the end of the next annual general
meeting, shall consist of nine ordinary board members without deputies and
elected Guðmundur Pálmason and Sigurgeir Guðlaugsson as new ordinary board
members in addition to the current board of directors. Consequently, the
members of the board of directors shall thereafter consist of Lennart Nilsson
(chairman of the board), Marianne Dicander Alexandersson, Jonas E Forsberg,
Anders Jungbeck, Hans Pihl, Nils Siegbahn, Monica Wallter, Guðmundur Pálmason
and Sigurgeir Guðlaugsson. The resolution is conditional upon, and shall have
effect as of the date of the completion of the acquisition of Zymetech.

Instructions and rules of procedures for the nomination committee's
appointment

The meeting resolved in accordance with the proposal of the board of directors
that the nomination committee, until a new nomination committee is appointed,
shall include Guðmundur Pálmason in addition to the current representatives
of the nomination committee, and that Guðmundur Pálmason shall remain in the
nomination committee regardless of significant changes in ownership of
Enzymatica. The resolution is conditional upon, and shall have effect as of
the date of the completion of the acquisition of Zymetech.

The English text is an unofficial translation. In case of any discrepancies
between the Swedish text and the English translation, the Swedish text shall
prevail.

For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB

Tel: +46 708-86 53 70 | E-post:fredrik.lindberg@enzymatica.com

About Enzymatica AB

Enzymatica is a life science company whose business concept is to offer
effective help against some of our most common diseases where viruses or
bacteria play a decisive role. Over a short period the company has developed
a unique oral spray for colds, ColdZyme®, and launched it on six markets. The
product has become one of the leading articles for colds in Swedish
pharmacies. Development includes medical devices in upper respiratory
infections and oral health, and veterinary products. The company is
headquartered in Lund, Sweden and is listed on Nasdaq First North. For more
information, please visitwww.enzymatica.com.

Press release (PDF)
http://hugin.info/160850/R/1986144/728609.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Enzymatica AB via Globenewswire

HUG#1986144

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.